Binding Term Sheet Supports Growth Plans
Scilex Holding Company (NASDAQ:SCLX) shares climbed 7% on Monday after the company announced it had signed a binding term sheet for a proposed $100 million strategic investment from Kazakhstan-based private investment firm iHolding Group LLP.
Under the proposed agreement, iHolding would acquire approximately 6.7 million newly issued Scilex common shares at $15.00 per share.
The company said the investment would provide additional capital to support its long-term expansion strategy across healthcare and medical technology.
Funding Targeted at Expansion and Acquisitions
If completed, the financing would be used to accelerate several strategic initiatives, including product development, commercialization activities, acquisitions and general working capital requirements.
Scilex also intends to invest in expanding its healthcare and medical technology programmes as it seeks to broaden its portfolio and strengthen future growth.
Transaction Subject to Closing Conditions
The proposed investment has not yet been finalized and remains subject to customary conditions, including due diligence, negotiation and execution of definitive agreements, board approvals, shareholder approval and any necessary regulatory clearances.
Until those steps are completed, there is no certainty that the transaction will proceed on the proposed terms.
Investment Highlights International Interest in Healthcare
Scilex specializes in acquiring, developing and commercializing non-opioid therapies for the treatment of acute and chronic pain, while also advancing treatments targeting neurodegenerative and cardiometabolic diseases.
According to the company, the proposed financing would represent one of the largest healthcare investments from Kazakhstan into a U.S.-listed biopharmaceutical company in recent years.